Jim Cramer: Don't Buy This Health Care Stock Yet, It Is 'Still Too Expensive'
Benzinga·2025-11-13 13:20

Group 1: Doximity, Inc. (NYSE:DOCS) - Doximity reported quarterly earnings of 45 cents per share, exceeding the analyst consensus estimate of 38 cents per share [1] - The company achieved quarterly sales of $168.525 million, surpassing the analyst consensus estimate of $157.614 million [1] - Jim Cramer advised waiting before purchasing Doximity shares, stating they are "still too expensive" [1] Group 2: IREN Limited (NASDAQ:IREN) - IREN reported quarterly earnings of $1.08 per share, significantly beating the consensus estimate of 14 cents [2] - The company's quarterly revenue was $240.3 million, exceeding the Street estimate of $235.5 million and up from $49.57 million in the same period last year [2] - Jim Cramer recommended selling half of IREN stock [2] Group 3: Boise Cascade Company (NYSE:BCC) - Boise Cascade reported quarterly earnings of 58 cents per share, missing the analyst consensus estimate of 76 cents per share [3] - The company reported quarterly sales of $1.668 billion, which beat the analyst consensus estimate of $1.623 billion [3] - Jim Cramer expressed concerns about the housing sector and suggested that Boise Cascade is too leveraged to a specific part of the market [3] Group 4: Price Action - Doximity shares fell 3.3% to settle at $50.96 [5] - IREN shares declined 2.9% to close at $55.70 [5] - Boise Cascade shares rose 0.9% to settle at $70.28 [5]